Rxo (RXO) Cost of Revenue (2021 - 2026)

Rxo (RXO) has 6 years of Cost of Revenue data on file, last reported at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 1.56% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (up 15.18% YoY), and the FY2025 full-year result was $4.6 billion, up 29.34% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.2 billion, down from $1.2 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.4 billion in Q4 2024 and bottomed at $699.0 million in Q1 2024.
• The 5-year median for Cost of Revenue is $857.0 million (2022), against an average of $937.5 million.
• The widest annual swing landed in 2023, when Cost of Revenue retreated 25.66%; it then jumped 82.64% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $842.0 million in 2022, then retreated by 11.76% to $743.0 million in 2023, then jumped by 82.64% to $1.4 billion in 2024, then fell by 11.35% to $1.2 billion in 2025, then dropped by 2.66% to $1.2 billion in 2026.
• The last three Cost of Revenue figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison